Barclays lowered its rating on Biogen  (BIIB) - Get Report shares to equal weight from overweight, after the biotech recently lost an important patent case with a generic-drug maker.Gould also said his conviction about aducanumab, a human monoclonal antibody that treats Alzheimer's disease, "has waned in the wake of delays, a lack of clarity around points of discussion with [the] FDA, and a seemingly less confident stance" on the drug.